Category Archives: Cf

Former Royal Jarrod Dyson gets a crack at his former team in Thursday's series opener. (AP)

Jarrod Dyson was a member of two playoff teams while playing for the Kansas City Royals, but hell be in the lineup against his old team Thursday trying to help the Mariners make up ground on the Royals in their own push for a postseason berth.

Dyson, who played in back-to-back World Series and won one with Kansas City, will hit seventh and play center field in his first game at Kauffman Stadium with a visiting team in a 5:15 game on 710 ESPN Seattle.

Mariners pitchers James Paxton, Edwin Diaz win monthly awards

The Mariners enter the big four-game series 1 1/2 games back of Kansas City for the second Wild Card spot from the American League.

Yovani Gallardo starts on the mound for Seattle against one of the Royals newest players, veteran right-hander Trevor Cahill.

Coverage begins with the pregame show at 4 on 710 ESPN Seattle. Here are the full lineups.

Mariners (55-54)

Ben Gamel, RF Jean Segura, SS Robinson Cano, 2B Nelson Cruz, DH Kyle Seager, 3B Danny Valencia, 1B Jarrod Dyson, CF Guillermo Heredia, LF Mike Zunino, C

Yovani Gallardo, RHP

Royals (55-51)

Whit Merrifield, 2B Lorenzo Cain, CF Melky Cabrera, RF Eric Hosmer, 1B Salvador Perez, C Mike Moustakas, 3B Brandon Moss, DH Alcides Escobar, SS Alex Gordon, LF

Trevor Cahill, RHP

See more here:

Mariners CF Jarrod Dyson in lineup for return to Kansas City - MyNorthwest.com

CF Industries Holdings, Inc. (CF - Free Report) was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $27.58 $31.14 in the past one-month time frame, witnessed a sharp increase yesterday.

The move came after the company reported solid second-quarter 2017 results

The company has seen three negative estimate revisions in the past two months, while its Zacks Consensus Estimate for the current quarter has also moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

CF Industries currently has a Zacks Rank #4 (Sell) while its Earnings ESPis positive.

CF Industries Holdings, Inc. Price and Consensus

A better-ranked stock in the Fertilizersindustry is Sociedad Quimica y Minera S.A.(SQM - Free Report) , which currently carries a Zacks Rank #2 (Buy). You can seethe complete list of todays Zacks #1 Rank (Strong Buy) stocks here.

Is CF going up? Or down? Predict to see what others think: Up or Down

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>

Continued here:

CF Industries Holdings, Inc. (CF) Looks Good: Stock Jumps 7% August 04, 2017 - Zacks.com

(Reuters) - U.S. fertilizer producer CF Industries Holdings Inc (CF.N) reported a 93.6 percent fall in quarterly profit on Wednesday and said it expects nitrogen pricing to be challenged through 2017 and into 2018.

Fertilizer prices have faced pressure from soft crop prices and expanding U.S. nitrogen fertilizer capacity.

The average selling price for ammonia fell nearly 18 percent to $338 per ton in the second quarter, while the price of UAN (urea ammonium nitrate) dropped about 13 percent to $175 per ton.

The Deerfield, Illinois-based company's net earnings fell to $3 million, or 1 cent per share, in the quarter ended June 30, from $47 million, or 20 cents per share, a year earlier.

The company recorded a derivative loss of $18 million in the latest reported quarter.

Net sales fell marginally to $1.12 billion.

Industry peer Mosaic Co (MOS.N) on Tuesday forecast slower phosphate sales and weaker prices for the third quarter.

Shares of CF were marginally down at $28.55 in after-hours trading on Wednesday.

Reporting by John Benny in Bengaluru; Editing by Maju Samuel

More:

Fertilizer maker CF Industries posts 93.6 percent plunge in profit - Reuters

Bicycling

The Canyon Spectral CF 9.0 EX Trail Bike Is Just Begging You to Fly Bicycling As the trail bike category continues to expand, cyclists no longer have to choose between a bike that's fun to climb and jump on and one that can plow through rubble. More bikes do it all, and they're doing it all better than ever. The Canyon Spectral ...

Here is the original post:

The Canyon Spectral CF 9.0 EX Trail Bike Is Just Begging You to Fly - Bicycling

Treatment with Alcresta Therapeutics product Relizorb effectively increased fat absorption in patients with cystic fibrosis (CF) receiving enteral tube feeding who have trouble breaking down and absorbing these molecules. This resulted in a reduction of the frequency and severity of gastrointestinal symptoms.

These findings were published recently in the Journal of Pediatric Gastroenterology & Nutrition, in a studytitled Increased Fat Absorption from Enteral Formula Through an In-line Digestive Cartridge in Patients with Cystic Fibrosis.

CF patients who lack the ability to absorb fat molecules receive enteral feeding to improve their nutrition.

Relizorb was evaluated in a study (Study 497) that spanned 27 days and included 33 pediatric and adult patients (ages ranging from 5 to 45 years, with a mean age of 14.5 years) with exocrine pancreatic insufficiency (EPI) associated with CF, and who had been receiving enteral feeding for approximately seven years.

Researchers analyzed fat absorption through the changes in plasma levels of relevant fatty acids, namely the omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). DHA and EPA are energy sources and essential components of cell membranes, and are involved in several body functions necessary for the maintenance of normal development and overall health.

Contrary to placebo, treatment with Relizorb induced a significant improvement (2.8-fold) in the total levels of DHA and EPA absorption. Also, RELiZORB use during the administration of enteral nutrition among these patients was safe and well-tolerated. Patients reported a decrease in the frequency and severity of gastrointestinal symptoms, particularly stool-related symptoms, associated with deficient fat absorption.

The publication of Study 497 is an important milestone as we build evidence in support of RELiZORB in this patient population, Daniel Tass, Alcresta Therapeuticss CEO, said in a press release. Patients who receive enteral nutrition often struggle to maintain a healthy nutritional status, and often miss out on consumption of critical calories. The results of this study provide us with the first well-controlled, randomized, double-blind study that showed improvements of fat absorption in patients on enteral nutrition within just 24 hours of treatment with RELiZORB, he said.

The increase in DHA and EPA plasma levels in the 497 study demonstrates that this strategy can increase absorption of fats and in particular critical healthy omega-3 fatty acids said study researcher Steven Freedman, MD, PhD. These are potentially important clinical benefits for patients who are put on nighttime enteral feedings but are waking up full, not eating breakfast and not benefitting from the positive caloric value that having a meal offers. This study is evidence of an important option that is now available to help these patients and their physicians meet important nutritional goals, Freedman said.

The active ingredient in Relizorb is the digestive enzyme lipase, attached to polymeric carriers together called immobilized lipase (iLipase). As the enteral tube feeding formula passes through Relizorb, it makes contact with the iLipase components and the fat in the formula is broken down to its absorbable form (fatty acids and monoglycerides) prior to ingestion. This method allows the absorption of 90 percent of the fats present in most enteral feeding tube formulas, including DHA and EPA.

Read the original here:

Relizorb Improves Nutritional Status in Tube-Fed CF Patients, Study Finds - Cystic Fibrosis News Today

Buy or Sell? Average Brokerage Ratings on Vornado Realty Trust (VNO), CF Industries Holdings, Inc. (CF) StockNewsJournal CF Industries Holdings, Inc. (NYSE:CF), maintained return on investment for the last twelve months at -1.91, higher than what Reuters data shows regarding industry's average. The average of this ratio is 5.77 for the industry and sector's best figure ... and more »

Read more:

Buy or Sell? Average Brokerage Ratings on Vornado Realty Trust (VNO), CF Industries Holdings, Inc. (CF) - StockNewsJournal

Earnings Clues on CF Industries Holdings, Inc. (CF), Brookdale Senior Living Inc. (BKD) Analyst's Predictions StockNewsJournal CF Industries Holdings, Inc. (CF) have shown a high EPS growth of -17.80% in the last 5 years and has earnings decline of -140.10% yoy. Analysts have a mean recommendation of 2.60 on this stock (A rating of less than 2 means buy, hold within the 3 ... and more »

Originally posted here:

Earnings Clues on CF Industries Holdings, Inc. (CF), Brookdale Senior Living Inc. (BKD) Analyst's Predictions - StockNewsJournal

Chronic pulmonary infections are a hallmark of lung disease in patients with cystic fibrosis. Due to the variability in bacteria that can colonize the lung and the specific antibiotic treatments that may be effective, treatment strategies are often tailored to individual patients.

But some bacterial infections are often difficult to treat across the entire population. Burkholderia cepaciacomplex (Bcc) is notoriously difficult to attack due to its natural multi-drug resistant state and its quick ability to develop resistance to antibiotics. Infections arising from Bcc can lead to permanent loss of lung function and early death in patients with CF.

Earlier this month, Synspira announced the resultsof a combination study using its inhaled polycationic glycopolymer drug candidate called PAAG and conventional antibiotics as a potential treatment for pulmonary infection caused by theBurkholderia cepaciacomplex in patients with CF.

The investigative treatment, SNSP113, is a glycopolymer-based therapy being developed as an inhaled treatment to improve lung function in patients with pulmonary bacterial infections.

SNSP113 is known to interact with the biofilms that make treating bacteria difficult in CF, and is thought to break the biofilms apart and reduce the viscosity and adhesion of mucus in the lungs. Biofilms and mucus lead to pulmonary exacerbations in CF, and SNSP113 may address both issues in cystic fibrosis.

The results published in PLOS ONE demonstrate that our inhaled glycopolymer drug candidate, PAAG, has the potential to significantly enhance the activity of antibiotics that are used for the treatment of lung infections caused by Burkholderia cepaciacomplex, a relatively uncommon but often fatal infection in cystic fibrosis,Shenda Baker, PhD,the CEO ofSynspira, said in a press release.

From a personal viewpoint, Bcc is one of those bacteria that makes me anxious to see my culture report. Its a scary one, and requires an intensive treatment plan in hopes to eradicate the bacteria from the lungs.

Part of the reason its nerve-racking is because there really are no bulls-eye treatments that have been approved to help preserve lung function. The bacteriums susceptibility to antibiotics varies tremendously, and there is a chance that no antibiotic may be effective to fight the infection.

The introduction of SNSP113 could be a game-changer in CF. If approved, the treatment would not only open up treatment options for Bcc, but may also have positive outcomes when treating other common infections in CF, like Pseudomonas. While much of the attention in cystic fibrosis has been directed toward the novel CFTR modulators, its still critically important to strive for new antibiotics in patients with CF.

***

Note:Cystic Fibrosis News Todayis strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Cystic Fibrosis News Todayor its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to cystic fibrosis.

Read the original here:

Synspira's Therapy Candidate May Be a Game-Changer for Drug-Resistant Bacteria in CF - Cystic Fibrosis News Today

The U.S. Food and Drug Administration (FDA) has approved Kalydeco (ivacaftor) to treat more than 600 of the estimated 30,000 Americans with cystic fibrosis (CF), Vertex Pharmaceuticals announced.

The oral medicine may now be prescribed to CF patients ages 2 and older who have one of five residual function mutations that result in a splicing defect in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, according to Vertex.

The FDA based its Aug. 1 approval on Phase 3 clinical data for Kalydeco in these mutations. This follows previous FDA approvalsof the drug in May 2017 for 23 other residual function mutations. The agencys first approval of Kalydeco was in January 2012 for 10 mutations in the CFTR gene.

Tuesdays announcement brings the number of CFTR mutations that Kalydeco may treat to 38 out of a possible 2,000 or so known mutations in the gene. Boston-based Vertex said both 2017 FDA approvals are supported by more than five years of real-world clinical experience that demonstrates Kalydecos established safety and effectiveness.

In the five years since Kalydeco became the first approved medicine to treat the underlying cause of cystic fibrosis, we have been relentless in our efforts to bring this important medicine to all who may benefit, Dr. Jeffrey Chodakewitz, executive vice president and chief medical officer at Vertex, said in a press release. We will continue to pursue this goal until all people with CF have a medicine that treats their form of this serious and life-shortening disease.

Kalydeco is the first medicine to treat the underlying cause of CF in people with those specific CFTR mutations. It is designed to keep CFTR proteins at the cell surface open longer to improve the transport of salt and water across the cell membrane, which helps hydrate and clear mucus from the airways.

According to Vertex, the five mutations covered under the FDAs latest approval cause CF and result in a moderate loss of chloride transport. Patients with these mutations generally experience progressive lung function decline and other complications of the disease. All five mutations were evaluated as part of the previously disclosedPhase 3 EXPAND studyin which Kalydeco as a monotherapy met its primary efficacy endpoint and was generally well tolerated.

Following the FDA announcement, Vertex raised projected 2017 sales of Kalydeco to between $770 million and $800 million. It now expects total CF product revenues to reach anywhere from $1.87 billion to $2.1 billion; well over half that total will come from sales of another CF therapy, Orkambi.

Kalydecos discovery stems from a CF research program initiated by Vertex in 2000 as part of a collaboration with Cystic Fibrosis Foundation Therapeutics, an affiliate of the nonprofit Cystic Fibrosis Foundation, based in Bethesda, Maryland.

See the article here:

FDA Approves Kalydeco for 600 CF Patients with Specific Mutations - Cystic Fibrosis News Today

Zacks Earnings ESP (Expected Surprise Prediction) looks to find earnings surprises by focusing on the most recent analyst revisions. This is done because, generally speaking, if an analyst reevaluates their earnings estimate right before an earnings release, it means that they have fresh information which could potentially be more accurate than what analysts thought about a company two or three months ago.

The crux of this approach is comparing the Most Accurate Estimate to the Zacks Consensus Estimate, although the Zacks Rank is also an important feature of the ESP metric. Combining these two can help investors find stocks that are ready to beat the consensus at their next report, and hopefully surge higher in price too.

In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time. And best of all, by using these parameters, investors have seen 28.3% annual returns on average, according to our 10 year backtest.

Visit the Earnings ESP Center

See the Full List of Stocks To Beat Earnings

Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.

The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest.

Visit the Earnings ESP Center

See the Full List of Stocks To Beat Earnings

( = Change in last 30 days)

View All Zacks Rank #1 Strong Buys

More Premium Research

Continued here:

Cf Industries Holdings, Inc. - CF - Stock Price Today - Zacks